Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
Authors
Keywords
Triple-negative breast cancer, TNBC, Breast cancer, Heat shock protein, HSP90, Ganetespib, Resistance, JAK, STAT
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-24
DOI
10.1186/s12885-019-5295-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
- (2016) Chengguang Zhao et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Resistance to HSP90 inhibition involving loss of MCL1 addiction
- (2015) S Busacca et al. ONCOGENE
- Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG
- (2014) Katie E Hadley et al. BMC CANCER
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)
- (2014) A Awada et al. CANCER RESEARCH
- Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
- (2014) D. A. Proia et al. CANCER RESEARCH
- Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation
- (2014) Hong Qiong Yan et al. CANCER SCIENCE
- A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
- (2014) Komal Jhaveri et al. Clinical Breast Cancer
- The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer
- (2014) SHU-WEI WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism
- (2014) Jaime Acquaviva et al. MOLECULAR CANCER RESEARCH
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
- (2014) H Landmann et al. Cell Death & Disease
- Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
- (2013) D. A. Proia et al. CLINICAL CANCER RESEARCH
- Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
- (2013) Julie C. Friedland et al. INVESTIGATIONAL NEW DRUGS
- A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
- (2013) Dan Zhou et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Interleukin-6 signaling pathway in targeted therapy for cancer
- (2012) Yuqi Guo et al. CANCER TREATMENT REVIEWS
- Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer
- (2012) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
- (2012) Pasquale Sansone et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
- (2012) Cole Trapnell et al. Nature Protocols
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
- (2009) N. Gaspar et al. CANCER RESEARCH
- Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
- (2008) Marissa V. Powers et al. CANCER CELL
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation